tiprankstipranks
Advertisement
Advertisement

CGON Stock Latest News

CG Oncology reports Q1 EPS (71c), consensus (54c)
The FlyCG Oncology reports Q1 EPS (71c), consensus (54c)
2d ago
CGON
CG Oncology price target raised to $79 from $73 at RBC Capital
PremiumThe Fly
CG Oncology price target raised to $79 from $73 at RBC Capital
13d ago
CGON
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
20d ago
CGON
SMMT
JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’
PremiumThe Fly
JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’
23d ago
JNJ
CGON
CG Oncology price target raised to $84 from $72 at BofA
PremiumThe Fly
CG Oncology price target raised to $84 from $72 at BofA
26d ago
CGON
CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
PremiumCompany AnnouncementsCG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
27d ago
8K
CGON
JPMorgan healthcare analysts hold an analyst/industry conference call
Premium
The Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
1M ago
CGON
TARA
CG Oncology price target raised to $100 from $80 at H.C. Wainwright
Premium
The Fly
CG Oncology price target raised to $100 from $80 at H.C. Wainwright
1M ago
CGON
CG Oncology price target raised to $90 from $60 at UBS
PremiumThe Fly
CG Oncology price target raised to $90 from $60 at UBS
1M ago
CGON
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
PremiumRatings
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
2M ago
CGON
CG Oncology price target raised to $72 from $65 at BofA
PremiumThe Fly
CG Oncology price target raised to $72 from $65 at BofA
2M ago
JNJ
CGON
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
PremiumRatings
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
2M ago
CGON
CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
PremiumRatingsCG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
2M ago
CGON
CG Oncology price target raised to $80 from $75 at H.C. Wainwright
Premium
The Fly
CG Oncology price target raised to $80 from $75 at H.C. Wainwright
2M ago
CGON
CG Oncology reports FY25 EPS ($2.08), consensus (58c)
Premium
The Fly
CG Oncology reports FY25 EPS ($2.08), consensus (58c)
2M ago
CGON
CG Oncology sees cash runway into 1H29
PremiumThe Fly
CG Oncology sees cash runway into 1H29
2M ago
CGON
CG Oncology price target raised to $75 from $66 at Truist
PremiumThe Fly
CG Oncology price target raised to $75 from $66 at Truist
3M ago
CGON
CG Oncology price target raised to $73 from $61 at RBC Capital
PremiumThe Fly
CG Oncology price target raised to $73 from $61 at RBC Capital
4M ago
CGON
CG Oncology price target raised to $70 from $55 at Piper Sandler
PremiumThe Fly
CG Oncology price target raised to $70 from $55 at Piper Sandler
4M ago
CGON
Oncolytics appoints John McAdory as EVP, strategy and operations
PremiumThe FlyOncolytics appoints John McAdory as EVP, strategy and operations
4M ago
CGON
ONCY
CG Oncology Expands At-The-Market Equity Offering Capacity
Premium
Company Announcements
CG Oncology Expands At-The-Market Equity Offering Capacity
4M ago
8K
CGON
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
AIM
CGON

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >